PRE-EXISTING AND ACQUIRED MORE FREQUENT KD MUTATIONS OF BCR-ABL IN PRIMARY AND SECONDARY RESISTANT IMATINIB-TREATED CML PATIENTS

被引：0
|
作者：
Vrsalovic, M. Marusic [1 ]
Duic, I. [1 ]
Ajdukovic, R. [1 ]
Haris, V. [1 ]
Pejsa, V. [1 ]
Jaksic, O. [1 ]
Kusec, R. [1 ]
机构：
[1] Dubrava Univ Hosp, Zagreb, Croatia
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1316
引用
收藏
页码：533 / 534
页数：2
相关论文
共 50 条
  • [41] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    E Jabbour
    H Kantarjian
    D Jones
    M Talpaz
    N Bekele
    S O'Brien
    X Zhou
    R Luthra
    G Garcia-Manero
    F Giles
    M B Rios
    S Verstovsek
    J Cortes
    Leukemia, 2006, 20 : 1767 - 1773
  • [42] In patients with chronic myelogeneous leukemia (CML), response dynamics to nilotinibafter imatinib failure depend on thetype of BCR-ABL mutations
    Soverini, S.
    Saglio, G.
    Branford, S.
    Radich, J.
    Kim, D. W.
    Hughes, T.
    Mueller, M.
    Erben, P.
    Hochhaus, A.
    Shou, Y.
    Weitzman, A.
    Baccarani, M.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 320 - 320
  • [43] Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia
    Leder, Kevin
    Foo, Jasmine
    Skaggs, Brian
    Gorre, Mercedes
    Sawyers, Charles L.
    Michor, Franziska
    PLOS ONE, 2011, 6 (11):
  • [44] ANALYSIS OF BCR-ABL MUTATIONS IN MEXICAN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT PHILADELPHIA-CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH plus CML) TREATED WITH NILOTINIB
    Ayala, J. L.
    Hurtado, R.
    Delgado, N.
    Vargas, P.
    Meillon, L.
    Tapia, N.
    Alvarado, M.
    De Diego, J.
    Azaola, P.
    Gonzalez, M.
    Lugo, Y.
    Hernandez, R.
    Kassack, J. J.
    Cleto, S.
    Nambo, M.
    Reyes, G.
    Cantu, O.
    Aguayo, A.
    Mucius, I.
    Herrera, A.
    Nacho, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 220 - 220
  • [45] ANALYSIS OF THE RELATIONSHIP BETWEEN DOSE AND BCR-ABL HALVING TIME IN CP-CML PATIENTS TREATED WITH PONATINIB OR IMATINIB
    Pritchard, J.
    Lustgarten, S.
    Hodgson, J. G.
    Baccarani, M.
    Cortes, J. E.
    Deininger, M. W.
    Guilhot, F.
    Hughes, T. P.
    Shah, N. P.
    Talpaz, M.
    Mueller, M. C.
    Clackson, T.
    Haluska, F. G.
    Knickerbocker, R.
    Rivera, V. M.
    HAEMATOLOGICA, 2015, 100 : 448 - 449
  • [46] Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Hochhaus, Andreas
    Kim, Dong-Wook
    Martinelli, Giovanni
    Hughes, Timothy P.
    Soverini, Simona
    Branford, Susan
    Muller, Martin C.
    Erben, Philipp
    Haque, Ariful
    Shou, Yaping
    Saglio, Giuseppe
    Radich, Jerald P.
    BLOOD, 2008, 112 (11) : 1103 - 1104
  • [47] Bcr-Abl mutations in imatinib-resistant CML and Ph plus ALL patients (pts) enrolled in a phase I study of AMN107.
    Ottmann, O.
    Bhalla, K.
    Kantarjian, H.
    Hochhaus, A.
    Jones, D.
    Dawson, K.
    Rose, K.
    Alland, L.
    Dugan, M.
    Lilleburg, S.
    Giles, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 343S - 343S
  • [48] Interferon prior to imatinib therapy eradicates pre-existing BCR-ABL ATP-binding domain mutations conferring natural imatinib resistance and leads to more sustained/durable molecular response in chronic myeloid leukaemia
    Iqbal, Z.
    Baig, S. M.
    Aziz, Z.
    Shah, I. H.
    Khalid, M.
    Iqbal, M.
    Tanveer, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 41 - 41
  • [49] Dynamics of BCR-ABL mRNA transcript expression in newly diagnosed CML patients treated with imatinib or interferon alpha.
    Mueller, MC
    Gattermann, N
    Lahaye, T
    Deininger, MW
    Berndt, A
    Fruehauf, S
    Reckzeh, B
    Fischer, T
    Kreil, S
    Merx, K
    Gschaidmeier, H
    Hehlmann, R
    Hochhaus, A
    BLOOD, 2002, 100 (11) : 365A - 365A
  • [50] Determination of BCR-ABL overexpression by correlating qRT-PCR and IP-FISH in imatinib treated CML patients
    Bianchini, Michele
    Gargallo, Patricia
    Alu, Fernand
    Barreyro, Paula
    Rosales, Belen
    Bengio, Raquel
    De Brasi, Carlos
    Larripa, Irene
    BLOOD, 2007, 110 (11) : 582A - 582A
12345